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Pystatin-C and Mortality in
lderly Persons With Heart Failure
ichael G. Shlipak, MD, MPH,* Mark J. Sarnak, MD,† Ronit Katz, PHD,‡ Linda Fried, MD, MPH,§
tephen Seliger, MD, Anne Newman, MD, MPH,¶ David Siscovick, MD, MPH#
atherine Stehman-Breen, MD, MS**
an Francisco and Thousand Oaks, California; Boston, Massachusetts; Seattle, Washington;
nd Pittsburgh, Pennsylvania
OBJECTIVES We sought to evaluate cystatin-C, a novel measure of renal function, as a predictor of
mortality in elderly persons with heart failure (HF) and to compare it with creatinine.
BACKGROUND Renal function is an important prognostic factor in patients with HF, but creatinine levels,
which partly reflect muscle mass, may be insensitive for detecting renal insufficiency.
METHODS A total of 279 Cardiovascular Health Study participants with prevalent HF and measures of
serum cystatin-C and creatinine were followed for mortality outcomes over a median of 6.5
years.
RESULTS Median creatinine and cystatin-C levels were 1.05 mg/dl and 1.26 mg/l. Each standard
deviation increase in cystatin-C (0.35 mg/l) was associated with a 31% greater adjusted
mortality risk (95% confidence interval [CI] 20% to 43%, p  0.001), whereas each standard
deviation increase in creatinine (0.39 mg/dl) was associated with a 17% greater adjusted
mortality risk (95% CI 1% to 36%, p 0.04). When both measures were combined in a single
adjusted model, cystatin-C remained associated with elevated mortality risk (hazard ratio
1.60, 95% CI 1.32 to 1.94), whereas creatinine levels appeared associated with lower risk
(hazard ratio 0.73, 95% CI 0.57 to 0.95).
CONCLUSIONS Cystatin-C is a stronger predictor of mortality than creatinine in elderly persons with HF. If
confirmed in future studies, this new marker of renal function could improve risk stratification
in patients with HF. (J Am Coll Cardiol 2005;45:268–71) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.061College of Cardiology Foundation
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Menal dysfunction is an important adverse prognostic factor
n patients with heart failure (HF) (1–3). However, the
tandard clinical measures of renal function—serum creati-
ine and creatinine-based estimates of glomerular filtration
ate (GFR)—may be less correlated with actual GFR in the
lderly (4). Cystatin-C, a novel serum measure of renal
unction (5), is a serine protease inhibitor that is released
rom all functioning cells. Although studies suggest that
ystatin-C may better approximate GFR than creatinine
5–7), their associations with HF outcomes have not been
ompared. In this pilot study, we compared cystatin-C with
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ohort of elderly patients with HF.
ETHODS
articipants. The Cardiovascular Heath Study (CHS) is a
ommunity-based, longitudinal study of adults65 years of
ge at entry. The objective of the study was to evaluate risk
actors for the development and progression of cardiovas-
ular disease (8). The original cohort of 5,201 study partic-
pants was recruited between 1989 and 1990, and an
dditional 687 African Americans were recruited in 1992
nd 1993. Follow-up interviews to identify potential clinical
vents were done semi-annually.
This study includes the 279 participants with prevalent HF
t the 1992 to 1993 visit of CHS. An expert panel adjudicated
iagnoses of HF on the basis of published criteria (9,10). The
tudy design was approved by the Institutional Review Board
f the University of Washington.
redictors. RENAL FUNCTION. Cystatin-C was measured
rom samples collected at the 1992 to 1993 visit and stored
t 70°C, using a BNII nephelometer (Dade Behring Inc.,
eerfield, Illinois) and a particle-enhanced immunoneph-
lometric assay (N Latex Cystatin-C, Dade Behring) (11).
Serum creatinine was measured using the Kodak Ek-
achem 700 Analyzer (Eastman Kodak, Rochester, New
ork), a colorimetric method. We used the simplified
odification of Diet in Renal Disease (MDRD) equationo estimate GFR from serum creatinine.
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January 18, 2005:268–71 Cystatin-C and Mortality in HFOVARIATES. Candidate variables for adjustment included
emographic characteristics (age, gender, race, and educa-
ion level); medical history (diabetes, hypertension, smoking
tatus, alcohol intake, body mass index, myocardial infarc-
ion [MI] [before 1992 to 1993 visit], stroke, coronary
evascularization procedure, claudication, and cancer [all
efore 1992 to 1993 visit]; chronic obstructive pulmonary
isease [from the 1989 to 1990 visit]); fibrinogen,
-reactive protein, lipid, and hemoglobin levels from the
992 to 1993 visit; electrocardiographic findings (left ven-
ricular hypertrophy and atrial fibrillation); and medication
se (aspirin, diuretics, angiotensin-converting enzyme in-
ibitors, beta-blockers, and calcium antagonists).
utcome. The outcomes of interest were all-cause mortal-
ty. Follow-up began at the 1992 to 1993 visit and contin-
ed until June 30, 2001.
nalysis. We compared participants with HF who sur-
ived with those who died during follow-up. To evaluate
easures of renal function as predictors of mortality,
ystatin-C and creatinine were evaluated as continuous
ariables per standard deviation. We used multivariate Cox
roportional hazards models that were adjusted for all the
forementioned characteristics as candidate predictors. Co-
ariates whose entry into the model changed the coefficient
f cystatin-C by 5% were retained and included in the final
odels for cystatin-C, creatinine, and estimated GFR. The
djustment variables were age, gender, body mass index,
revious stroke, cancer, hypertension, anemia, and lipid-
owering medications. Hypertension was defined as systolic
lood pressure 140 mm Hg, and anemia was defined as
emoglobin 12 g/dl for men and 13 g/dl for women.
e also evaluated models that included both cystatin-C and
reatinine. We did not evaluate estimated GFR as a
ontinuous variable because of the implications of modeling
atios in regression analyses, in particular, problems with
purious correlations and the loss of scientific interpretation
f the coefficient by adjusting for GFR (12).
We evaluated the association of quartiles of estimated
FR, cystatin-C, and creatinine as predictors of mortality.
reatinine quartiles were gender-specific to ensure adequate
epresentation of men and women within each. We deter-
ined the unadjusted and multivariate-adjusted risk for
uartiles 2 through 4 compared with quartile 1. Multivariate
nalyses were done using the covariates selected for contin-
ous variable analyses.
We compared the adjusted mortality risk of participants
Abbreviations and Acronyms
CHS  Cardiovascular Health Study
CI  confidence interval
GFR  glomerular filtration rate
HF  heart failure
HR  hazard ratio
MI  myocardial infarctionith cystatin-C levels above and below the median value dfter stratifying the cohort by the median creatinine and
stimated GFR levels. S-Plus (release 6.1, Insightful Inc.,
eattle, Washington) and SPSS statistical software (release
2.0.0, SPSS Inc., Chicago, Illinois) were used for the
nalyses.
ESULTS
uring a median follow-up time of 6.5 years (range 0.1 to
.1), 182 patients (65%) died, and the annual mortality risk
as 11.1%. Characteristics associated with mortality include
dvanced age, male gender, reduced body mass index, and
revious stroke (Table 1). Mean cystatin-C and creatinine
evels were significantly higher and estimated GFR was
ower among the participants who died during follow-up.
A change of one standard deviation in cystatin-C (0.34
g/l) was associated with a mortality risk in unadjusted
nalyses (hazard ratio [HR] 1.31, 95% confidence interval
CI] 1.20 to 1.43), and this association was unchanged after
ultivariate adjustment (HR 1.31, 95% CI 1.17 to 1.47). A
hange of one standard deviation in creatinine (0.39 mg/dl)
as less strongly associated with mortality risk (HR 1.23,
5% CI 1.12 to 1.36), and the point estimate was attenuated
omewhat by multivariate adjustment (HR 1.17, 95% CI
.01 to 1.36). When both measures were combined in a
ingle adjusted model, cystatin-C remained associated with
levated mortality risk (HR 1.60, 95% CI 1.32 to 1.94),
hereas creatinine levels appeared associated with lower risk
able 1. Baseline Characteristics of Participants With Heart
ailure by Survival During Follow-Up
Characteristic
Alive
(n  97)
Dead
(n  182) p Value
ge (yrs) 74  5 78  6  0.0001
ale 37 (38%) 101 (56%) 0.01
frican American 22 (23%) 28 (15%) 0.13
igh school graduate 63 (65%) 106 (58%) 0.45
ody mass index (kg/m2) 29  5 27  5  0.0001
iabetes 25 (26%) 54 (30%) 0.49
revious MI 40 (41%) 75 (41%) 1.00
revious stroke 8 (8%) 36 (20%) 0.01
revious revascularization 16 (17%) 17 (9%) 0.08
ancer 14 (15%) 36 (22%) 0.19
ystolic blood pressure
(mm Hg)
136  25 136 24 0.96
iastolic blood pressure
(mm Hg)
68  13 68 14 0.86
otal cholesterol (mg/dl) 203 40 195 40 0.12
DL cholesterol (mg/dl) 122 36 118 33 0.34
DL cholesterol (mg/dl) 49 13 49 14 0.91
RP (mg/dl) 9.0 16.8 8.4 13.3 0.76
emoglobin (g/dl) 13.4 1.5 13.2 1.7 0.17
trial fibrilation 7 (7%) 22 (12%) 0.20
eft ventricular hypertrophy 8 (8%) 13 (14%) 0.20
ystatin-C (mg/l) 1.18 0.29 1.46 0.53  0.0001
reatinine (mg/dl) 1.03 0.33 1.24 0.48  0.0001
stimated GFR
(ml/min/1.73 m2)
70  18 62 22 0.001
ata are presented as the mean value  SD or number (%) of subjects.
CRP  C-reactive protein; GFR  glomerular filtration rate; HDL  high-
ensity lipoprotein; LDL  low-density lipoprotein; MI  myocardial infarction.
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xclude colinearity as an explanation for this finding, as the
orrelation of the two measures was high (r  0.80).
After multivariate adjustment, the highest quartile of
ystatin-C (1.55 mg/l) was associated with a two-fold
ortality risk, whereas the lower three quartiles had similar
isk (Table 2). We repeated the analyses with the inclusion
f all candidate covariates and found that the results were
ssentially unchanged: HRs of 1.00 and 0.92 (95% CI 0.51
o 1.69), 1.37 (95% CI 0.70 to 2.68), and 2.16 (95% CI 1.17
o 4.00) for quartiles 1 through 4. Although the highest
uartile of creatinine had elevated mortality risk on unad-
usted analysis, this association was not significant on
djusted analysis. After multivariate adjustment, the highest
uartile of estimated GFR was associated with a 60%
reater mortality risk than the lowest quartile (Table 2).
We evaluated the association of cystatin-C levels above
nd below the median value (1.26 mg/l) with mortality after
tratifying by the median creatinine (1.05 mg/dl) and
stimated GFR levels (61 ml/min/1.73 m2) (Fig. 1). Par-
icipants with cystatin-C levels above the median value were
t similarly elevated mortality risk, regardless of whether
heir creatinine or estimated GFR levels were above or
elow the median value.
ISCUSSION
ystatin-C was an independent predictor of mortality in
lderly persons with HF. Persons with cystatin-C levels in
he highest quartile (1.55 mg/l) had a two-fold adjusted
ortality risk compared with those in the lowest quartile.
lthough creatinine levels were associated with mortality in
linear model, the association of cystatin-C with mortality
as greater in magnitude and persisted even after adjust-
Table 2. Quartiles of Renal Function and Mor
1st Quartile 2nd Qu
Cystatin-C
Range 1.03 1.04–
n 69 71
Annual risk 7% 10
Unadjusted HR 1.00 1.49 (0.9
Adjusted HR* 1.00 1.04 (0.6
Creatinine
Range in women 0.45–0.75 0
Range in men 0.75–0.95 1.05–
n 77 70
Annual risk 9% 11
Unadjusted HR 1.00 1.32 (0.8
Adjusted HR* 1.00 0.97 (0.6
Estimated GFR
Range 80.96 61.80–
n 70 69
Annual risk 7% 12
Unadjusted HR 1.00 1.64 (1.0
Adjusted HR* 1.00 1.20 (0.7
*Adjusted for age, gender, body mass index, previous stroke,
GFR  glomerular filtration rate; HR  hazard ratio.ent for creatinine. This novel measure of renal function
w
mould potentially improve the risk stratification of elderly
atients with HF.
Previous studies have found that renal dysfunction, mea-
ured by creatinine or estimated GFR, is a strong predictor
f mortality in the setting of HF (1–3). Because creatinine
evels are influenced heavily by muscle mass, estimated GFR
s recommended by the National Kidney Foundation as the
ppropriate renal function measure for clinicians (13). How-
ver, estimates of GFR may not be optimal in persons with
ormal creatinine levels (14). Cystatin-C may overcome
ome of the limitations of creatinine and estimated GFR, as
Risk in Elderly Patients With Heart Failure
3rd Quartile 4th Quartile
1.27–1.55 1.56
70 69
12% 19%
7) 1.89 (1.21–2.96) 3.35 (2.17–5.17)
0) 1.18 (0.70–1.99) 2.15 (1.30–3.54)
0.95–1.05 1.15–4.05
1.35–1.45 1.55–3.05
54 78
10% 16%
0) 1.19 (0.75–1.89) 2.01 (1.36–2.98)
4) 1.01 (0.62–1.64) 1.38 (0.88–2.16)
49.28–61.79 49.27
71 69
10% 17%
5) 1.37 (0.87–2.14) 2.67 (1.75–4.09)
5) 0.77 (0.47–1.26) 1.62 (1.01–2.59)
r, hypertension, anemia, and lipid-lowering medication.
igure 1. Association of cystatin-C levels with mortality in elderly persons
ith heart failure, stratified by creatinine (Cr) and estimated glomerular
ltration rate (eGFR) levels. The figure displays the annual mortality risk
or participants with cystatin-C levels above (high) or below (low) the
edian of 1.26 mg/l. The adjusted hazard ratios (HR) compare high versus
ow cystatin-C levels among subgroups of participants with high creatinine
above median value of 1.05 mg/dl) or low creatinine (1.05 mg/dl), as
2tality
artile
1.26
%
4–2.3
4–1.7
.85
1.25
%
7–2.0
1–1.5
80.96
%
5–2.5
4–1.9ell as by high eGFR (61 ml/min/1.73 m ) or low eGFR (61
l/min/1.73 m2).
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ass.
tudy limitations. This study has certain important limi-
ations. The small sample size of participants with HF
imited the power to detect differences across the lower
uartiles of each renal function measure or to conduct
ubgroup analyses by gender and race. This is a sample of
lderly subjects with HF, so we do not know whether
ystatin-C would have advantages over creatinine in
ounger patients or those with different diagnoses. In
ddition, although we presume that the association of
ystatin-C with mortality is caused by its correlation with
FR, we cannot exclude the possibility that circulating
ystatin-C levels either have directly harmful effects or
eflect another pathologic process distinct from renal
unction.
onclusions. Independent of both creatinine and tradi-
ional risk factors, cystatin-C is a strong predictor of
ortality in persons with HF. Further study will be needed
o confirm this finding and to determine whether measure-
ent of cystatin-C would have clinical benefits in the care
f elderly patients with HF.
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